Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Secondary Hyperparathyroidism (SHPT) occurs in many patients with kidney disease and leads to bone disease. Active forms of vitamin D, calcitriol and paricalcitol, treat SHPT, but may have different effects on blood calcium. This study will randomize patients with SHPT and stage 3 or 4 CKD to treatment with calcitriol or paricalcitol, and monitor patients for the incidence of high blood calcium, and effectiveness of SHPT treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborators: Abbott; Feinberg School of Medicine, Northwestern University; Henry Ford Hospital; NorthShore University HealthSystem
• Treatments: Calcitriol; Ergocalciferols

Criteria

Inclusion Criteria

1. Age >18; Able to give informed consent

2. Chronic kidney disease, and estimated GFR 15 to 60 ml/min using the abbreviated MDRD equation

3. intact PTH (iPTH) >120 pg/ml at baseline

4. albumin corrected calcium > 8.5 mg/dL to < 10.0 mg/dL at baseline

5. Phosphorus < 4.6 mg/dL at baseline

6. If on a phosphorus binder; no change in dose within the 4 weeks prior to screening

Exclusion Criteria

1. Receiving any active form of vitamin D within 4 weeks prior to screening (calcitriol, doxercalciferol; paricalcitol; alfacalcidol)

2. Receiving >50,000 IU per month of ergocalciferol or > 1000 IU of cholecalciferol per day within the previous 30 days.

3. history of primary HPT

4. On prednisone > 30 days within the previous 6 months

5. receiving bisphosphonates or calcitonin within the previous 12 months

6. Non-elective hospitalization within the previous 30 days.

7. Expected to initiate dialysis or receive a kidney transplant within the next 6 mo.

8. History of renal or other organ transplant

9. History of parathyroidectomy or previous diagnosis of primary hyperparathyroidism

10. Receiving cinacalcet within 4 weeks prior to screening.

11. An active drug/alcohol dependence or abuse history

12. History of non-compliance with visits or medications that preclude study compliance in the opinion of the investigator

13. Pregnant, or able to become pregnant and unwilling to use a birth control method considered reliable by the principal investigator